Deucravacitinib: A first-in-class oral treatment for psoriasis.

The first-in-class, once daily oral therapy deucravacitinib has been PBS listed in Australia for adults with severe chronic plaque psoriasis. Deucravacitinib represents a new option for treating plaque psoriasis with its unique mechanism of action as a selective tyrosine kinase 2 inhibitor. [ABSTRACT FROM AUTHOR]